Lupin Q1 FY26 earnings preview: Will the pharma main maintain its progress, margin positive aspects, and turnaround momentum? Key expectations, peer tendencies, and outlook.
Lupin Q1 FY26 outcomes: Sustaining the comeback momentum?

Leave a comment